Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma

被引：2
|
作者：
Hamlin, Paul A. [1 ,2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Basking Ridge Med Oncol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Oncol, Dept Med, New York, NY 10065 USA
[3] New York Presbyterian Hosp, Dept Med, Weill Cornell Med Coll, New York, NY 10032 USA
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(16)30157-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1023 / 1025
页数：4
相关论文
共 50 条
  • [31] Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab
    Verriere, B.
    Gastaud, L.
    Chamorey, E.
    Peyrade, F.
    Deletie, E.
    Bouredji, K.
    Quinsat, D.
    Schiappa, R.
    Thyss, A.
    Re, D.
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 144 - 149
  • [32] Optimal Cycles of Bendamustine-Plus Rituximab Therapy for Indolent B Cell Lymphoma
    Toyama, Kazuhiro
    Takezaki, Toshiaki
    Honda, Akira
    Kogure, Yasunori
    Chiba, Akira
    Nakamura, Fumihiko
    Nakazaki, Kumi
    Kurokawa, Mineo
    BLOOD, 2019, 134
  • [33] Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Pott, Christiane
    Belada, David
    Danesi, Nathalie
    Fingerle-Rowson, Guenter
    Gribben, John
    Harbron, Chris
    Hoster, Eva
    Kahl, Brad S.
    Mundt, Kirsten
    Sebban, Catherine
    Sehn, Laurie H.
    Cheson, Bruce D.
    BLOOD, 2015, 126 (23)
  • [34] Bendamustine plus rituximab in MALT lymphoma
    Ferreri, Andres J. M.
    LANCET HAEMATOLOGY, 2014, 1 (03): : E88 - E89
  • [35] Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
    Garau M.
    Hampson G.
    Devlin N.
    Mazzanti N.A.
    Profico A.
    PharmacoEconomics - Open, 2018, 2 (2) : 153 - 163
  • [36] Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
    Friedberg, Jonathan W.
    Cohen, Philip
    Chen, Ling
    Robinson, K. Sue
    Forero-Torres, Andres
    La Casce, Ann S.
    Fayad, Luis E.
    Bessudo, Alberto
    Camacho, Elber S.
    Williams, Michael E.
    Van der Jagt, Richard H.
    Oliver, Jennifer W.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 204 - 210
  • [37] Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Ta, Jamie T.
    Seetasith, Arpamas
    Wang, Rongrong
    Lai, Dominic
    Shapouri, Sheila
    BLOOD, 2021, 138
  • [38] Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Buchheit, Vincent
    Frey, Nicolas
    Brewster, Michael
    Fingerle-Rowson, Gunter
    Jamois, Candice
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1935 - 1945
  • [39] Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
    Ma, Jun
    Zhao, Donglu
    Zhen, Bihong
    Xia, Yan
    Gong, Qianyi
    Chen, Wendong
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (12)
  • [40] Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma
    Pott, C.
    Belada, D.
    Danesi, N.
    Fingerle-Rowson, G.
    Gribben, J.
    Harbron, C.
    Hoster, E.
    Kahl, B.
    Mundt, K.
    Sebban, C.
    Sehn, L. H.
    Cheson, B. D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 93 - 94
12345